Patel Sushil: insider trades.
Patel Sushil reported 11 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 0 open-market purchases and 10 sales ($1.6M), across 2 companies.
- Transactions
- 11
- Purchases (P)
- 0
- Sales (S)
- 10
- Companies
- 2
- Name as filed
- Patel Sushil
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Revolution Medicines, Inc. (RVMD) | Director | 10 |
| Replimune Group, Inc. (REPL) | Director, Officer · Chief Executive Officer | 1 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-08-10 | Replimune Group, Inc. | S | 39,341 | $12.97 | 708,151 | Form 4 |
| 2026-06-29 | Revolution Medicines, Inc. | S | 300 | $183.17 | 26,936 | Form 4 |
| 2026-06-29 | Revolution Medicines, Inc. | S | 900 | $184.59 | 26,036 | Form 4 |
| 2026-06-29 | Revolution Medicines, Inc. | S | 1,100 | $185.9 | 24,936 | Form 4 |
| 2026-06-29 | Revolution Medicines, Inc. | S | 881 | $192.61 | 21,656 | Form 4 |
| 2026-06-29 | Revolution Medicines, Inc. | S | 300 | $187.83 | 23,778 | Form 4 |
| 2026-06-29 | Revolution Medicines, Inc. | S | 100 | $188.57 | 23,678 | Form 4 |
| 2026-06-29 | Revolution Medicines, Inc. | S | 600 | $190.55 | 23,078 | Form 4 |
| 2026-06-29 | Revolution Medicines, Inc. | S | 541 | $191.87 | 22,537 | Form 4 |
| 2026-06-29 | Revolution Medicines, Inc. | M | 2,955 | $37.54 | 27,236 | Form 4 |
| 2026-06-29 | Revolution Medicines, Inc. | S | 858 | $186.92 | 24,078 | Form 4 |
Questions
What stock did Patel Sushil buy or sell?
Patel Sushil reported 11 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 0 open-market purchases and 10 sales ($1.6M), across 2 companies.
Is Patel Sushil the same person as other filers with this name?
This page covers SEC CIK 1860609 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/patel-sushil-1860609.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.